FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
ELOX Financial Statements
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
3.64M
4.14M
5.48M
6.03M
Research and Development
1.25M
2.34M
3.49M
3.3M
Selling, General & Administrative Expenses
2.39M
1.8M
2M
2.73M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
2.39M
1.8M
2M
2.73M
Other Expenses
0
8k
0
0
Operating Income
-3.64M
-4.14M
-5.48M
-6.03M
Total Other Income/Expenses Net
45k
-201k
-747k
-291k
Income Before Tax
-3.59M
-4.34M
-6.23M
-6.32M
Income Tax
0
238k
0
658k
Net Income
-3.59M
-4.34M
-6.23M
-6.32M
Basic EPS
-1.31
-1.96
-2.88
-2.92
EPS Diluted
-1.31
-1.96
-2.88
-2.92
Basic Average Shares
2.75M
2.21M
2.17M
2.17M
Diluted Average Shares
2.75M
2.21M
2.17M
2.17M
EBITDA
-3.17M
-3.93M
-5.56M
-5.56M
Retained Earning Schedule
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Retained Earnings (Previous Year)
-284.96M
-280.62M
-274.39M
-268.07M
Net Income
-3.59M
-4.34M
-6.23M
-6.32M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-288.55M
-284.96M
-280.62M
-274.39M
Other Distributions
-3.59M
-4.34M
-6.23M
-6.32M
PPE Schedule
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Gross PPE
413k
611k
797k
994k
Annual Depreciation
188k
185k
186k
178k
Capital Expenditure
0
0
0
0
Net PPE
225k
426k
611k
816k
Intangible and Goodwill Schedule
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
